<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolized. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to decrease of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to decrease of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Do not take a progestin treatment fewer than 12 hours after stopping the ulipristal.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the estrogen-progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolised. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolized. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT" code="G03-003" /></DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Chose a therapeutic alternative that is little or not at all metabolized.</COMMENT>
</INTERACTION>
</INTERACTIONS>
